SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.

Trial Details

NCT ID
NCT07857616
Phase
PHASE1
Sponsor
SystImmune Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • SI-B036
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Orlando, Florida, United States|28.53834,-81.37924
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Documented locally advanced or metastatic solid tumor(s) not amenable to curative surgery or radiation and have received at least 1 line of standar…
  • Toxicity of previous antitumor therapy has returned to level ≤1 as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adver…
  • Has no serious cardiac dysfunction and left ventricular ejection fraction ≥50%.
  • Has adequate organ function before enrollment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →